Cargando…

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

Acute myeloid leukemia (AML) with t(8;21) is categorized as favorable-risk AML, but KIT mutations show a significantly poor prognostic impact in such patients. Persistent vulnerability to relapse is a major challenge in the treatment of this subtype of patients. Venetoclax is a BCL-2 selective inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zheng, Wang, Jun, Ge, Shuai-Shuai, Qiu, Qiao-Cheng, Du, Jia-Hui, Shan, Shuang-Shuang, Shen, Xiang-Dong, Wan, Chao-Ling, Wang, Bin-Ru, Wu, De-Pei, Qiu, Hui-Ying, Xue, Sheng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861361/
https://www.ncbi.nlm.nih.gov/pubmed/35211416
http://dx.doi.org/10.3389/fonc.2022.841276
_version_ 1784654869509963776
author Li, Zheng
Wang, Jun
Ge, Shuai-Shuai
Qiu, Qiao-Cheng
Du, Jia-Hui
Shan, Shuang-Shuang
Shen, Xiang-Dong
Wan, Chao-Ling
Wang, Bin-Ru
Wu, De-Pei
Qiu, Hui-Ying
Xue, Sheng-Li
author_facet Li, Zheng
Wang, Jun
Ge, Shuai-Shuai
Qiu, Qiao-Cheng
Du, Jia-Hui
Shan, Shuang-Shuang
Shen, Xiang-Dong
Wan, Chao-Ling
Wang, Bin-Ru
Wu, De-Pei
Qiu, Hui-Ying
Xue, Sheng-Li
author_sort Li, Zheng
collection PubMed
description Acute myeloid leukemia (AML) with t(8;21) is categorized as favorable-risk AML, but KIT mutations show a significantly poor prognostic impact in such patients. Persistent vulnerability to relapse is a major challenge in the treatment of this subtype of patients. Venetoclax is a BCL-2 selective inhibitor. The venetoclax+HMA strategy is also a notable salvage regimen that achieves good clinical outcomes in the treatment of relapsed or refractory (R/R) AML. However, in our clinical practice, we found that disease progressed rapidly even after venetoclax+azacitidine (AZA) therapy in two relapsed t(8;21) AML patients with KIT mutations. We report for the first time the therapeutic potential of venetoclax+midostaurin as a new combination therapy for relapsed t(8;21) AMLs with KIT mutations showing resistance to venetoclax+AZA therapy. Our ex vivo study also showed that midostaurin alone could inhibit proliferation and induce apoptosis of Kasumi-1 cells (e.g. Midostaurin induced G2 phase cell arrest, down-regulated p-KIT and BCL-2, while Bax protein levels were up-regulated) and observed a synergistic anti effect when the two drugs were combined. Our study shows that the venetoclax+midostaurin regimen may be a promising treatment option for R/R t(8;21) AML with KIT mutations.
format Online
Article
Text
id pubmed-8861361
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88613612022-02-23 Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment Li, Zheng Wang, Jun Ge, Shuai-Shuai Qiu, Qiao-Cheng Du, Jia-Hui Shan, Shuang-Shuang Shen, Xiang-Dong Wan, Chao-Ling Wang, Bin-Ru Wu, De-Pei Qiu, Hui-Ying Xue, Sheng-Li Front Oncol Oncology Acute myeloid leukemia (AML) with t(8;21) is categorized as favorable-risk AML, but KIT mutations show a significantly poor prognostic impact in such patients. Persistent vulnerability to relapse is a major challenge in the treatment of this subtype of patients. Venetoclax is a BCL-2 selective inhibitor. The venetoclax+HMA strategy is also a notable salvage regimen that achieves good clinical outcomes in the treatment of relapsed or refractory (R/R) AML. However, in our clinical practice, we found that disease progressed rapidly even after venetoclax+azacitidine (AZA) therapy in two relapsed t(8;21) AML patients with KIT mutations. We report for the first time the therapeutic potential of venetoclax+midostaurin as a new combination therapy for relapsed t(8;21) AMLs with KIT mutations showing resistance to venetoclax+AZA therapy. Our ex vivo study also showed that midostaurin alone could inhibit proliferation and induce apoptosis of Kasumi-1 cells (e.g. Midostaurin induced G2 phase cell arrest, down-regulated p-KIT and BCL-2, while Bax protein levels were up-regulated) and observed a synergistic anti effect when the two drugs were combined. Our study shows that the venetoclax+midostaurin regimen may be a promising treatment option for R/R t(8;21) AML with KIT mutations. Frontiers Media S.A. 2022-02-08 /pmc/articles/PMC8861361/ /pubmed/35211416 http://dx.doi.org/10.3389/fonc.2022.841276 Text en Copyright © 2022 Li, Wang, Ge, Qiu, Du, Shan, Shen, Wan, Wang, Wu, Qiu and Xue https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Zheng
Wang, Jun
Ge, Shuai-Shuai
Qiu, Qiao-Cheng
Du, Jia-Hui
Shan, Shuang-Shuang
Shen, Xiang-Dong
Wan, Chao-Ling
Wang, Bin-Ru
Wu, De-Pei
Qiu, Hui-Ying
Xue, Sheng-Li
Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
title Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
title_full Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
title_fullStr Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
title_full_unstemmed Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
title_short Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
title_sort combination of venetoclax and midostaurin efficiently suppressed relapsed t(8;21)acute myeloid leukemia with mutant kit after failure of venetoclax plus azacitidine treatment
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861361/
https://www.ncbi.nlm.nih.gov/pubmed/35211416
http://dx.doi.org/10.3389/fonc.2022.841276
work_keys_str_mv AT lizheng combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT wangjun combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT geshuaishuai combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT qiuqiaocheng combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT dujiahui combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT shanshuangshuang combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT shenxiangdong combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT wanchaoling combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT wangbinru combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT wudepei combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT qiuhuiying combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment
AT xueshengli combinationofvenetoclaxandmidostaurinefficientlysuppressedrelapsedt821acutemyeloidleukemiawithmutantkitafterfailureofvenetoclaxplusazacitidinetreatment